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A B S T R A C T
Hepatitis B virus (HBV) genotype and precore and basal core promoter (BCP) mutants in the 
patients with persistently normal alanine aminotransferase (ALT) and low serum HBV-DNA 
levels are unclear. The aim of this study was to determine HBV genotypes, precore and BCP 
mutations, and their association with chronic hepatitis and liver fibrosis in HBV-infected 
patients with persistently normal ALT, and low serum HBV-DNA levels in northeast China. 
Patients (n = 89) with normal ALT and serum HBV-DNA levels below 20000 IU/mL but 
detectable with real-time PCR were included in this study. HBV genotypes were determined 
by real-time PCR. The precore and BCP mutations were detected by sequencing. All the 
patients had biopsy results. Of the 89 patients, 11 (12.4%) were genotype B and 78 (87.6%) 
were genotype C. The most common mutations were G1896A (23.6%), G1764A (9.0%), and 
A1762T (6.7%). The prevalence of precore mutation was significantly higher in genotype B 
patients than in genotype C patients (54.5% vs. 19.2%, p < 0.01). There was no significant 
difference in the prevalence of BCP mutations between genotype B and genotype C (18.2% 
vs. 10.2%). Multivariate analysis showed that old age (> 40 years) and BCP mutations were 
independent predictors of liver necroinflammation and fibrosis. Thus, BCP mutations 
may be associated with liver necroinflammation and fibrosis in patients with persistently 
normal ALT and low serum HBV-DNA levels in northeast China.
Introduction
Hepatitis B virus (HBV) infection is a public health problem 
worldwide. It is estimated that approximately 3 billion people 
have been exposed to HBV, of whom more than 350 million 
are chronically infected.1 Based on an intergroup divergence 
of 8% or more in the full-length nucleotide sequence, HBV has 
been classified into 8 major genotypes (designated from A to 
H), and most of them show a distinct geographic distribution.2,3 
Genotypes B and C are the predominant HBV genotypes in 
Eastern Asia, including China.4 There is growing evidence that 
HBV genotypes are associated with severity of liver diseases, 
certain prognoses, and response to antiviral therapies.4-7 
Original Article
Hepatitis B virus genotypes, precore mutations, and basal 
core promoter mutations in HBV-infected Chinese patients 
with persistently normal alanine aminotransferase and low 
serum HBV-DNA levels 
Ming Shia*, Yong Zhanga, Jing Zhangb, Wei Liua, Lu Xinga  
aCentral Laboratory, No.6 Hospital of Dalian, Liaoning Province, China 
bDepartment of Clinical Laboratory, Dalian Central Hospital, Liaoning Province, China
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
 BRAZ J INFECT DIS. 2012;16(1):52-56 53
In addition to natural polymorphic variances, HBV can 
evolve certain variants in the precore and basal core promoter 
(BCP) regions.8,9 The G to A substitution at nucleotide 1896 
(G1896A) is one of the most common mutations in the precore 
region, which prevents the production of hepatitis B e antigen 
(HBeAg) by introducing a premature stop codon into the open 
reading frame of the precore region. Thus, this mutation is 
frequently detected in patients with HBeAg-negative chronic 
hepatitis B.10 Another common mutation is a double mutation 
in BCP region involving an A to T substitution at nucleotide 1762 
and a G to A substitution at nucleotide 1764 (A1762T/G1764A), 
which aborts the transcription of precore mRNA but does not 
seriously affect that of viral pregenome RNA.11 Although the 
frequencies of the precore and BCP mutations vary between 
HBV genotypes, they are associated with fulmimant hepatitis 
B and hepatocellular carcinoma (HCC).12,13
The level of circulating viraemia is a risk factor for the 
development of cirrhosis and HCC, and is used to diagnose 
hepatitis B infection and define the response to antiviral 
therapy.14,15 Since chronic hepatitis, cirrhosis and HCC have 
been found in patients with low serum HBV DNA-levels, the 
current cutoff value of 20,000 IU/mL is still debatable. Further 
understanding the virological characteristics in patients with 
low HBV-DNA levels will be helpful for clinical decisions 
in management of patients with low circulating viraemia. 
Many studies have demonstrated that HBV genotype and 
precore and BCP mutants have a substantial impact on the 
progression of chronic hepatitis B. However, few of them have 
been performed in patients with persistently normal alanine 
aminotransferase (ALT) and low serum HBV DNA levels.4,16,17 
In the present study, we aimed to examine the prevalence 
of HBV genotypes and G1896A mutation and A1762T/G1764A 
double mutations and their association with status of chronic 
hepatitis B in HBV-infected patients with persistently normal 
ALT and low serum HBV-DNA levels in Liaoning, a northeast 
province of China.
Material and methods
Study population and samples
From May 2003 to December 2009, 89 patients were 
selected from the patients attending Dalian Central Hospital 
and Dalian No. 6 Hospital (a hospital for infectious diseases). 
Patients were all HBsAg positive for at least six months and 
had detectable serum HBV-DNA but lower than 20,000 IU/mL 
by real-time PCR. All the patients were monitored for ALT 
levels every month, and the results were consistently normal 
(lower than 30 IU/L) for at least six months before enrollment. 
Patients were excluded from the study if they had any of the 
following conditions: 1) previous treatment for HBV infection, 
2) co-infection with hepatitis A, C, D and E virus or HIV, 3) 
history of alcohol or drug abuse, and 4) other possible causes 
of chronic liver damage. Serum samples were collected from 
these patients and stored at -70oC until use. The study protocol 
conformed to the Declaration of Helsinki, and was approved by 
the Ethics Committees of the institutions. Every patient gave 
his/her informed consent for this study.
Detection of ALT, HBV DNA, and the serum markers of HBV 
infection
Hepatitis B surface antigen (HBsAg), hepatitis B surface 
antibody (HBsAb), HBeAg, anti-HBe, and hepatitis B 
core antibody (anti-HBc) were measured with commercially 
available reagents (Kehua Biotech, Shanghai, China) according 
to manufacturer’s instruction. ALT activity was determined 
kinetically on Hitachi 7600 automatic biochemistry analyzer 
with commercial kits (Roche Diagnostics – Penzberg, Germany). 
HBV-DNA levels were tested using real-time PCR kits (Fosun 
Diagnostics – Shanghai, China) on ABI Prism 7500 PCR 
System (Applied Biosystems Inc – Foster City, CA, USA). The 
lower detection limit of this kit is 100 IU/mL (500 copies/mL).18 
All reagents were approved by Chinese State Food and Drug 
Administration for in vitro diagnostic use.
Detection of G1896A precore mutation and A1762T/G1764A 
double mutations
Precore 1896 and BCP 1762/1764 mutations were assayed using 
direct DNA sequence analysis as described by Yang et al.13 
Briefly, HBV-DNA was isolated from 100 μL of serum sample 
with a QIAamp DNA Mini Kit (Qiagen – Hilden, Germany) 
according to the manufacturer’s instruction. HBV-DNA was 
amplified with nested PCR on an ABI 9600 thermocycler 
(Applied Biosystem – Foster City, CA, USA). Final PCR products 
were checked by agarose gel electrophoresis and purified 
before sequence analysis using ABI PRISM BigDye and ABI 
3730 sequencer (Applied Biosystem – Foster City, CA, USA), 
according to the manufacturer’s instruction.
Genotyping of HBV
HBV genotypes were determined by a commercial real-time 
PCR kit (Fosun Diagnostics – Shanghai, China). This kit was 
approved by Chinese State Food and Drug Administration for 
in vitro diagnosis use. The kit only detects HBV genotype B 
and C with a lower detection limit of 200 IU/mL. Samples that 
could not be detected by the real time PCR kit were subjected to 
DNA sequence analysis of the pre-S region of the HBV genome 
as described by Yeh et al.19
Histological assessment of the liver
The degree of hepatic inflammation and stage of fibrosis was 
determined with the use of Batts-Ludwig’s grading and staging 
system for chronic hepatitis.20 All the 89 patients had liver 
biopsy results.
Statistical analysis
Statistical analyses were performed with the Statistical Program 
for Social Sciences (SPSS 13.0 for Windows, SPSS, Chicago, IL, 
USA). Qualitative and quantitative data were compared by chi-
square test, Fisher’s exact test, and Mann-Whitney test, when 
applicable. The association between severity of histology and 
mutations was determined by multiple logistic regression. 
Statistical significance was denoted as a p-value less than 0.05.
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Results
Demographic and clinical characteristics of the patients
The study population consisted of 89 patients with low serum 
HBV DNA loads (detectable serum HBV-DNA but lower than 
20000 IU/mL). Twenty-nine of them were HBeAg negative 
and 60 were HBeAg positive. Liver biopsy showed chronic 
active hepatitis and cirrhosis in eight patients (9.0%). All 
the 60 HBeAg positive patients had HBV-DNA less than 
20000 IU/mL, ALT lower than 30 IU/L, and normal biopsy 
results. Twenty-one of the HBeAg negative patients were 
inactive HBV carriers (HBV-DNA less than 2000 IU/mL, 
ALT lower than 30 IU/L, and normal biopsy results). The 
demographic and clinical characteristics were shown in Table 1. 
Distribution of HBV genotypes
Of the 89 patients, 11 (12.4%) were genotype B and 
78 (87.6%) were genotype C. The B to C ratio showed 
significant differences between HBeAg positive and HBeAg 
negative patients (p < 0.05). Compared to patients with 
genotype C, patients with genotype B had lower viral load, 
higher HBeAg negative rate, and older (Table 2). 
HBV genotypes and precore and BCP mutations
The precore and BCP mutations occurred in 21 (23.6%) and 
10 (11.2%) patients, respectively (Table 2). The most common 
mutations were G1896A, G1764A, and A1762T [21 (23.6%), 
8 (9.0%), and 6 (6.7%), respectively]. Two patients (2.2%) 
had mixed mutations of G1896A and G1764A. Four 
(4.5%) patients had mixed mutations of A1762T/G1764A. 
One patient (1.1%) had G1764A/C1766G mutation. The 
prevalence of precore mutation was significantly higher in 
genotype B patients (54.5%) than in genotype C patients (19.2%, 
p < 0.01). However, there was no significant difference in the 
prevalence of BCP mutations between genotype B and genotype 
C patients. The precore and BCP mutations occurred more 
frequently in patients older than 40 years (p < 0.05).
All the 29 HBeAg negative patients had precore and/or BCP 
mutations [19 (65.5%) with precore mutation, 8 (27.6%) with 
BCP mutation, and 2 (6.9%) with mixed mutations of precore 
and BCP]. There were no significant differences in HBV-DNA 
levels between HBeAg positive and negative patients. Due to 
small number of genotype B patients in our study, we evaluated 
the relationship among HBV-DNA levels and precore and BCP 
mutations among patients with genotype C. HBV-DNA levels 
were significantly lower in patients with the precore mutation 
than in those without the mutation (p < 0.01). However, HBV-
DNA levels were significantly higher in patients with BCP 
mutations than in those without the mutations (p < 0.01). 
HBV genotypes, precore and BCP mutations, and histological 
assessment
There were 8 patients (9.0%) with necroinflammatory activity 
(G1-G2) and fibrosis (S1-S2) simultaneously. All the 8 patients 
were genotype C and had BCP mutations (three of them 
had mixed mutations of precore and BCP). Although two 
patients had BCP mutations among patients with genotype B, 
they had no liver inflammation or fibrosis. Logistic regression 
with the variables age (> 40 years), genotype, precore and BCP 
mutations, and HBV-DNA level (> 2000 IU/mL) showed that 
age and BCP mutations were independent predictors of liver 
necroinflammation and fibrosis. 
Discussion
Although treatment criteria for patients with HBV infection 
are well established, the optimal management of patients with 
persistently normal ALT levels and low serum HBV-DNA levels 
has always been debatable. It is now recognized that lower 
serum HBV-DNA levels may be associated with progressive 
liver disease and may warrant treatment, particularly in 
those who are HBeAg negative or have already developed 
cirrhosis.14 Currently, the widely accepted cut-off value of 
serum HBV-DNA is 20000 IU/mL (100000 copies/mL) for HBeAg 
positive patients and 2000 IU/mL for HBeAg negative patients, 
respectively. For patients with increased ALT and HBV-DNA 
above 20000 IU/mL, biopsy does not usually affect the decision 
for treatment.21 For patients with normal ALT and HBV-DNA 
< 20000 IU/mL, there are no any agreed diagnostic and 










22.3 ± 7.3 24.2 ± 5.7
HBV-DNA (log10 IU/mL)
Mean ± SD
3.43 ± 0.81 3.15 ± 0.32
Necroinflammation 0 8
Fibrosis 0 8





HBeAg- (%) 8 (72.8) 21 (26.9) < 0.01
HBV-DNA (log10 IU/mL) 
Mean ± SD
2.34 ± 0.58 3.76 ± 0.63 < 0.01
Age (Mean ± SD) 48 ± 5.5 39 ± 7.9 < 0.01
BCP mutation 2 (18.2) 8 (10.2) > 0.05
A1762T 1 (9.1) 1 (1.3) -
G1764A 1 (9.1) 3 (3.8) -
A1762T/G1764A 0 4 (5.1) -
Precore mutation 6 (54.5) 15 (19.2) < 0.01
G1896A 6 (54.5) 15 (19.2) < 0.01
Table 1 - Demographic, biochemical, and virological 
characteristics of the studied patients
Table 2 - Frequency of precore and basal core promoter 
mutations stratified by HBeAg, genotype, and histology
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treatment criteria. The virological characteristics in these 
patients also remain unclear. In the present study, we selected 
89 Chinese patients with persistently normal ALT and serum 
HBV-DNA < 20000 IU/mL but detectable with real-time PCR, 
to examine the prevalence of HBV genotypes, the precore 
mutation, BCP mutations, and their association with status 
of chronic hepatitis B. HBV genotype C (87.6%) was dominant 
in these patients. The precore and BCP mutations were 
observed in 23.6% and 11.2% of the patients, respectively. All 
the 29 HBeAg negative patients had precore or BCP mutations. 
Eight patients (9.0%) with genotype C, HBeAg negative, and 
BCP mutations were found with liver necroinflammation 
and fibrosis. These results imply that detection of BCP 
mutations may be a useful tool in management of patients 
with persistently normal ALT and low HBV-DNA levels in 
addition to liver biopsy. 
Previous studies show that the prevalence of precore 
and BCP mutations depends on HBV genotypes, and these 
mutations are related to fulminant and severe hepatitis 
and hepatocellular carcinoma.4,5,22-25 Some studies have 
reported that genotype C, BCP mutations, old age, high ALT 
levels and low albumin levels are associated with higher 
degree of necroinflammation as well as fibrosis by univariate 
analyses, and BCP mutations are associated with genotype 
C.26-28 However, only high ALT levels were independently 
correlated with high histological activity index (HAI) scores.26 
Our results show that the prevalence of BCP mutations has 
no significant differences between genotypes B and C. The 
discrepancy between our results and previous studies may 
be due to the small number of genotype B patients in our study 
and the special characteristics of our subjects. Our results 
also show that BCP mutations are associated with higher 
HBV-DNA levels in genotype C patients, and this is consistent 
with previous studies.29,30
Eight patients (9.0%) had liver necroinflammation and 
fibrosis in our study. All these patients were genotype C, HBeAg 
negative, older, and with BCP mutations. Two patients with 
BCP mutation and genotype B had normal liver histology. Yuen 
et al.26 reported that BCP mutations were associated with more 
severe necroinflammation but not with the degree of fibrosis. 
The eight patients in our study had necroinflammation and 
fibrosis simultaneously. However, the findings in our study 
were not sufficient to support the conclusion that the effects 
of BCP mutations exerted on necroinflammation might lead to 
liver fibrosis. Further studies are needed to clarify the effect 
of BCP mutations on the progression of chronic hepatitis B.
In conclusion, necroinflammation and fibrosis exist in 
Chinese patients with persistently normal ALT and low 
serum HBV-DNA levels. BCP mutations may be associated 
with liver necroinflammation and fibrosis in these patients. 
Further studies are needed to confirm the significance of such 
association.
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